Executive Summary

The Global Transcatheter Tricuspid Valve Intervention (TTVI) market is projected to display noteworthy growth and estimated to reach value of USD 10.17 billion by the year 2030 with Europe region leading the regional market share. Demand for transcatheter valvular therapeutics for tricuspid valve diseases in line with rising aged population globally that are more prone to such diseases is likely to boost the market growth. Moreover, tricuspid valve intervention (repair and replacement) device developments and their upcoming medical approvals across countries is also creating positive outlook for the market growth.

European region is estimated to be the fastest growing regional market for the TTVI in the forecast period of 2021-25, whereas Asia-Pacific will take the lead in the second half from 2026-30. The growth of the European market can be attributed to early approvals of some tricuspid valve repair devices, rising burden of tricuspid valve disorders, ageing population and high per-capita healthcare spending in regional countries. Whereas, APAC region growth will witness lucrative growth owing to factors like huge unmet needs of patients suffering from tricuspid valve disorders, rapidly expanding healthcare infrastructure, surge in medical tourism and rising healthcare spending by both public and private sectors in the regional countries. Meanwhile, North America will hold the second biggest share in TTVI market and will grow at a robust pace as well.

The emergence of COVID-19 has brought the world to a standstill. This health crisis has brought an unprecedented impact on businesses across industries, including the cardiovascular (heart) care and other related industries. The COVID-19 epidemic has disrupted the clinical & confirmatory trials, pipeline milestones, or regulatory clearances and approvals of tricuspid valve repair & replacement devices in different nations because of lockdowns, travel boycotts, and implementation of stay-at-home orders. With the suspension or delay of screening, medical associations approvals and clinical trial activities, COVID-19 has fundamentally reshaped clinical & surgical practice at every level.

Rising prevalence of tricuspid valve diseases, increasing preference for transcatheter tricuspid valve intervention devices for treatment, and technological advancements leading to enhanced applications of Transcatheter Tricuspid Valve Intervention. Furthermore, the growing preference for minimally-invasive surgeries over traditional/open heart surgeries will drive the utilization of TTVI procedures, such as valve repair and replacement interventions. These factors, in turn, are projected to fuel the demand for Transcatheter Tricuspid Valve Intervention over the coming years.

Scope of the Report

The report analyses the Transcatheter Tricuspid Valve Intervention Market by value (USD Millions).
The report analyses the Transcatheter Tricuspid Valve Intervention Market by Intervention Type (Tricuspid Valve Repair (TVr) and Tricuspid Valve Replacement (TVR)).
The report analyses the Transcatheter Tricuspid Valve Intervention Market by Disease Type (Tricuspid Regurgitation (TR) and Tricuspid Stenosis (TS))
The report analyses the Transcatheter Tricuspid Valve Intervention Market by End User (Hospitals, Ambulatory Surgical Centers, Others)
The Global Transcatheter Tricuspid Valve Intervention Market has been analysed By Region (North America, Europe, Asia Pacific, and LAMEA).
The Global Transcatheter Tricuspid Valve Intervention Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, and Australia).
The key insights of the report have been presented through the frameworks of SWOT Analysis and Product pipeline. Also, the attractiveness of the market has been presented by region, by Intervention Type, by Disease Type and by End User.
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product developments. The companies analysed in the report include Edwards Lifesciences, Abbott, Medtronic PLC, LivaNova PLC, CryoLife, Venus MedTech, NaviGate Cardiac Structures, Jenscare Biotech., Huihe Medical, and 4Tech Cardio Ltd.
The report presents the analysis of Transcatheter Tricuspid Valve Intervention Market for the forecast period of 2021-2030.
Key Target Audience
Transcatheter Tricuspid Valve Intervention Products Manufacturers
Pharmaceutical Industry
Biotechnology Companies
Government and Research Organisations
Consulting and Advisory Firms
Investment Banks and Equity Firms